ArticleCureus2026
Cytomegalovirus Retinitis Mimicking Acute Retinal Necrosis During Upadacitinib Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) retinitis classically occurs in patients with advanced human immunodeficiency virus infection but may also affect non-HIV patients with impaired cellular immunity and can resemble acute retinal necrosis (ARN). A 74-year-old woman receiving upadacitinib 15 mg/day for rheumatoid arthritis presented with decreased vision and a central dark scotoma in the left eye. Widefield montage imaging obtained with the Mirante SLO/OCT platform (NIDEK Co., Ltd., Gamagori, Aichi, Japan) showed temporal to inferotemporal retinal whitening with hemorrhages, vitreous haze, marked perivascular changes, and occlusive vasculitis. Intravenous acyclovir was started for presumed ARN. Aqueous humor polymerase chain reaction subsequently detected CMV DNA at 6.85 × 10⁴ copies/mL, whereas herpes simplex virus and varicella-zoster virus results were negative; HIV RNA was undetectable and peripheral-blood CMV antigenemia was negative. Treatment was changed to oral valganciclovir, and upadacitinib was discontinued. The valganciclovir dose was reduced after renal dysfunction developed. The retinal whitening regressed into atrophic scars without retinal detachment or fellow-eye involvement, but vision remained poor because of macular ischemia and outer retinal damage. This case illustrates that CMV retinitis in a non-HIV immunosuppressed patient may present with an ARN-like phenotype and severe occlusive vasculitis. Early ocular fluid testing can identify the pathogen and redirect antiviral treatment; the temporal association with upadacitinib should not be interpreted as proof of drug-specific causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.